Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Myriad Genetics Inc (NASDAQ:MYGN)

32.58
Delayed Data
As of Dec 12
 +0.10 / +0.31%
Today’s Change
15.15
Today|||52-Week Range
37.30
+95.44%
Year-to-Date
Genomic Health (GHDX) Oncotype DX Score Test Data Positive
Dec 12 / Zacks.com - Paid Partner Content
Omnicell's Rising Costs Affect Bottom Line Amid Competition
Dec 11 / Zacks.com - Paid Partner Content
Boston Scientific Receives FDA Nod for Vercise DBS System
Dec 12 / Zacks.com - Paid Partner Content
Myriad Genetics Presents Encouraging EndoPredict Test Data
Dec 11 / Zacks.com - Paid Partner Content
Smith & Nephew's Rotation Medical Deal Aids Tissue Regen Arm
Dec 12 / Zacks.com - Paid Partner Content
NxStage Nx2me Connected Health Improves Home Hemodialysis
Dec 11 / Zacks.com - Paid Partner Content
Hill-Rom (HRC) Banks on Strategic Buyouts, Competition Rife
Dec 12 / Zacks.com - Paid Partner Content
Cooper Companies (COO) Tops Q4 Earnings & Revenue Estimates
Dec 11 / Zacks.com - Paid Partner Content
Inogen Rides on Solid Product Portfolio Amid Forex Woes
Dec 12 / Zacks.com - Paid Partner Content
Vertex Kalydeco Study Successful in Children Aged 1-2 Years
Dec 08 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close32.48
Today’s open32.66
Day’s range32.28 - 33.13
Volume529,899
Average volume (3 months)979,915
Market cap$2.2B
Data as of 4:00pm ET, 12/12/2017

Growth & Valuation

Earnings growth (last year)-81.29%
Earnings growth (this year)-0.14%
Earnings growth (next 5 years)+9.30%
Revenue growth (last year)+2.33%
P/E ratio21.9
Price/Sales2.30
Price/Book2.85

Competitors

 Today’s
change
Today’s
% change
AAAPAdvanced Accelerator...-0.03-0.04%
NEOGNeogen Corp+0.75+0.95%
IMMUImmunomedics Inc-0.23-1.86%
QDELQuidel Corp-0.33-0.82%
Data as of 4:00pm ET, 12/12/2017

Financials

Next reporting dateFebruary 6, 2018
EPS forecast (this quarter)$0.24
Annual revenue (last year)$771.4M
Annual profit (last year)$21.8M
Net profit margin2.83%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark C. Capone
Executive Vice President-
International Operations
Gary A. King
Corporate headquarters
Salt Lake City, Utah

Forecasts